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Autoimmune hepatitis (AIH) is a chronic inflam-
matory disease of unknown etiology. There is
substantial evidence to show that genetic predis-
position is an important etiopathogenic factor of
AIH.1 In white populations in the West, suscepti-
bility to type 1 AIH is known to be associated with
HLA A1-B8-DR3 and DR4 antigens.2 Japanese
studies have shown that the genetic susceptibility
of Japanese AIH patients is associated with HLA-
DR4.3 Distinct results of HLA association have
also been reported in different countries, includ-
ing Argentina, Mexico, Brazil, and China.4–7 To
date, HLA typing data of AIH patients in Taiwan
have not been investigated or reported. We there-
fore investigated the HLA antigens and allelic
subtypes that were associated with AIH patients.
In this preliminary study, we performed HLA
phenotyping for loci A, B, C, DR and DQ in AIH
patients, and also compared the results with those
of normal subjects and patients with chronic
liver disease.
Methods
Study subjects
Forty-two patients with type 1 AIH were diagnosed
in Chi-Mei Medical Center, a tertiary referral cen-
ter in southern Taiwan. The patients were consec-
utively seen between April 2000 and September
2003. The diagnosis of AIH was made accord-
ing to the revised criteria of the International
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BRIEF COMMUNICATION
Autoimmune Hepatitis Group (IAIHG).8 Twenty-
two definite AIH patients were tested by HLA tissue
typing and comprised group 1. All patients in this
group were born in Taiwan, residing in Tainan
district. Age ranged from 28 to 72 years (median,
54.5 years); there were seven men and 15 women.
All patients had increased serum levels of aspar-
tate aminotransferase (AST; > 200 IU/L) and IgG
(> 1600 mg/dL) and were antinuclear antibody
(ANA) and/or smooth muscle actin (SMA) posi-
tive. All patients tested negative for hepatitis B and
C, had no history of blood transfusion, chronic
medication usage and alcoholic liver disease.
Other possible causes of liver diseases including
α1-antitrypsin disease, Wilson’s disease, scleros-
ing cholangitis and primary biliary cirrhosis were
excluded, and liver biopsies were done in 18 of
the 22 patients. Group 2 comprised 19 patients
with chronic liver disease, including hepatitis B,
hepatitis C and alcoholic liver disease. None had
a history of blood transfusion in the past 1 year.
ANA and SMA were tested in this group of patients
to exclude the possibility of superimposed AIH.
Group 3 (control) comprised 81 unrelated healthy
subjects who were normal blood donors. All tested
negative for hepatitis B and C, had normal serum
levels of AST and alanine aminotransferase, and
were age and sex matched with group 1.
All three groups of patients were tested for
HLA phenotypes (HLA-A, B, C, DR, DQ) using
the polymerase chain reaction–sequence specific
probe (PCR-SSP) method. The study was approved
by the ethics committee of Chi-Mei Medical
Center and informed consent was obtained from
each subject.
Serologic tests
Viral markers for hepatitis B and C were tested
using the Microparticle Enzyme Immunoassay
(Abbott Laboratories, Abbott Park, IL, USA).
HCV-RNA was measured by PCR. Serologic tests
for ANA, anti-SMA, antimitochondrial antibody
(AMA) and antineutrophil cytoplasmic antibody
(p-ANCA) were performed using the indirect im-
munofluorescence technique (Medical & Biological
Laboratories Co. Ltd., Nagoya, Japan).
HLA typing
Both HLA class I and class II phenotypes were de-
termined by the PCR-SSP method. Genomic DNA
was extracted from peripheral blood leukocytes.
HLA typing was then performed by PCR amplifi-
cation in the PTC 100TM Peltier thermer cycler PCR
system, with sequence-specific primers (Dynal
AllSetTM SSP; Dynal Biotech Ltd., Wirral, UK), 
according to the manufacturer’s instructions.
Amplification efficacy was checked with 1.5%
agarose gel electrophoresis and visualized with
ethidium bromide agarose gel staining. Image
acquisition was carried out using the Gel Doc 2000
documentation system (Bio-Rad Laboratories,
Nazareth Eke, Belgium).
Statistical analysis
Statistical analysis of laboratory results was per-
formed using Fisher’s exact test.
Results
The demographic data of the three groups are
shown in Table 1. The frequency of HLA antigens
(Classes I and II) in group 1 (AIH patients) was
compared to that in group 2 (chronic liver disease)
and group 3 (normal controls) (Tables 2 and 3).
It was found that the more frequent phenotypes
in AIH patients were DQ5 (50%), CW7 (50%),
A11 (55%), DR4 (36%) and DQ8 (27%). When
the AIH and control groups were compared, only
HLA-DQ5 was significantly more frequent in AIH
patients than in healthy subjects (50% vs. 25%;
relative risk [RR], 2.03; p = 0.034) (Table 3). The
incidence of CW7, A11, DR4 and DQ8 were some-
what higher than in normal controls but did not
reach statistical significance. When AIH patients
were compared to those with chronic liver dis-
ease, CW7, CW8, B60, CW10 and DQ5 appeared
more frequently in AIH patients, but the differ-
ence was not statistically significant. It is impor-
tant to specify that in this comparison, DQ5
showed a higher rate (50%) in AIH patients than
in chronic liver disease patients (37%) (Table 3),
but due to the small case number of group 2
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controls, no statistical significance was shown. 
It is of note that in these AIH patients, the fre-
quencies of A1 (n = 2/22), B8 (n = 1/22) and DR3
(n = 0/22) were very low compared to that in the
West, and among the prevalent types of HLA anti-
gens reported in the West, only HLA-DR4 showed
a higher frequency in our patients (n = 8/22),
although this did not reach statistical significance
HLA-DQ5 association with autoimmune hepatitis
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Table 1. Demographic data of subjects*
Autoimmune hepatitis Chronic liver disease Normal controls
(n = 22) (n = 19) (n = 81)
Age (yr) 54.5 (28–72) 48 (23–67) 45 (21–67)
Gender (M/F) 7/15 7/12 26/55
*Data are presented as median (range) or n.
Table 2. Frequency of HLA class I antigens in subjects
HLA
Group 1 Group 2 Group 3 
RR(1,2) p(1,2) RR(1,3) p(1,3)(n = 22) (n = 19) (n = 81)
A1 0.09 0.00 0.01 ∞ NS 7.36 NS
A11 0.55 0.53 0.40 1.04 NS 1.38 NS
(0.232)
A2 0.50 0.42 0.52 1.19 NS 0.96 NS
A24 0.27 0.42 0.42 0.65 NS 0.65 NS
A33 0.18 0.11 0.32 1.73 NS 0.57 NS
B13 0.14 0.11 0.16 1.30 NS 0.85 NS
B38 0.14 0.00 0.07 ∞ NS 1.84 NS
B46 0.18 0.37 0.21 0.49 NS 0.87 NS
B48 0.09 0.05 0.02 1.73 NS 3.68 NS
B55 0.09 0.16 0.01 0.58 NS 7.36 NS
B56 0.09 0.05 0.02 1.73 NS 3.68 NS
B58 0.18 0.11 0.28 1.73 NS 0.64 NS
B60 0.32 0.16 0.42 2.02 NS 0.76 NS
(0.292)
B61 0.09 0.00 0.11 ∞ NS 0.82 NS
B62 0.14 0.16 0.12 0.86 NS 1.10 NS
B75 0.09 0.11 0.11 0.86 NS 0.82 NS
B8 0.05 0.00 0.00 ∞ NS ∞ NS
CW1 0.27 0.58 0.28 0.47 NS 0.96 NS
CW9 0.14 0.16 0.11 0.86 NS 1.23 NS
CW10 0.32 0.16 0.33 2.02 NS 0.95 NS
(0.292)
CW12 0.09 0.11 0.11 0.86 NS 0.82 NS
CW15 0.09 0.05 0.05 1.73 NS 1.84 NS
CW7 0.50 0.21 0.35 2.38 NS 1.45 NS
(0.103) (0.219)
CW8 0.27 0.11 0.30 2.59 NS 0.92 NS
(0.249)
Group 1 = AIH patients; Group 2 = chronic liver disease patients; Group 3 = normal controls; RR(1,2) = relative risk of group 2 versus
group 1; p(1,2) = group 2 data compared with group 1 data using Fisher’s exact test; RR(1,3) = relative risk of group 3 versus group 1;
p(1,3) = group 3 data compared with group 1 data using Fisher’s exact test; NS = not significant.
when compared to normal controls (Table 3). The
most common HLA haplotype in our AIH pa-
tients was A2 DQ5. The frequencies of A2 DQ5
were 32% in group 1, 11% in group 2, and 14%
in group 3. Comparison results were p = 0.140 for
group 1 versus group 2, and p = 0.060 for group 1
versus group 3.
Discussion
AIH is a chronic inflammatory disease of unknown
etiology. Circumscribed evidence has shown that
the manifestations of AIH are a result of multiple
factors. These include: (1) a specific genetic back-
ground, such as HLA-DR3 or HLA-DR4;2,9 (2)
defects in the immunologic control of autoreac-
tivity;10 (3) environmental factors such as viral
infections, drugs or hepatotoxins triggering the
autoimmune process.11,12 The significance of 
genetic predisposition in the etiopathogenic role
of the disease has been extensively studied, and
striking genetic association for AIH susceptibility
has been reported.1,2 It is proposed that in per-
sons susceptible to AIH, an etiologic agent such
as a virus or toxin triggers the disease, with an en-
suing autoimmune response that is influenced by
the presence of certain HLA molecules.1,13 The
HLA molecules are genes linked to the class I and
II region of the major histocompatibility complex
(MHC) on chromosome 6.1,13 It has been shown
that 90% of white patients possessed either HLA-
DR3 or HLA-DR4 compared with 45–55% of the
normal population.2,9 In Japan, investigators
noted that their AIH patients are associated with
HLA-DR4 and, in contrast with Western patients,
HLA-A1-B8-DR3 molecules are extremely rare 
in Japanese AIH patients.3 Different results of
HLA associations with the disease has also been
reported in different geographic areas and ethnic
groups. Patients from Brazil have been shown 
to be associated genetically with HLA-DR13 
and DR52,6 whereas patients from Argentina are
associated with DR13 and DR4 (DRB1*0405),4
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Table 3. Frequency of HLA class II antigens in subjects
HLA
Group 1 Group 2 Group 3 
RR(1,2) p(1,2) RR(1,3) p(1,3)(n = 22) (n = 19) (n = 81)
DQ2 0.18 0.16 0.25 1.15 NS 0.74 NS
DQ4 0.14 0.16 0.11 0.86 NS 1.23 NS
DQ5 0.50 0.37 0.25 1.36 NS 2.03 0.034*
(0.531)
DQ6 0.27 0.26 0.40 1.04 NS 0.69 NS
DQ7 0.36 0.42 0.41 0.86 NS 0.89 NS
DQ8 0.27 0.21 0.14 1.30 NS 2.01 NS 
(0.191)
DQ9 0.14 0.26 0.27 0.52 NS 0.50 NS
DR11 0.14 0.32 0.21 0.43 NS 0.65 NS
DR12 0.23 0.11 0.25 2.16 NS 0.92 NS
DR14 0.14 0.05 0.10 2.59 NS 1.38 NS
DR15 0.27 0.21 0.23 1.30 NS 1.16 NS
DR17 0.18 0.05 0.19 3.45 NS 0.98 NS
DR4 0.36 0.37 0.22 0.99 NS 1.64 NS 
(0.716)
DR8 0.18 0.11 0.26 1.73 NS 0.70 NS
DR9 0.14 0.26 0.27 0.52 NS 0.50 NS
*Significant. Group 1 = AIH patients; Group 2 = chronic liver disease patients; Group 3 = normal controls; RR(1,2) = relative risk of
group 2 versus group 1; p(1,2) = group 2 data compared with group 1 data using Fisher’s exact test; RR(1,3) = relative risk of group 3 versus
group 1; p(1,3) = group 3 data compared with group 1 data using Fisher’s exact test; NS = not significant.
and patients from Mexico with DR4 (DRB1*
0404).5
HLA tissue typing of AIH is important as it
serves to clarify the genetic background of the
disease, which exerts great influence on disease
severity, clinical expression and treatment out-
come.14 Our previous studies have shown that
the AIH incidence in Taiwan is not as low as pre-
viously presumed.15,16 Indeed, the calculated 
incidence of type 1 AIH in our study (0.52/
100,000/year) is comparable to data from the
West (0.1–1.9/100,000/year).17 It is thus important
to determine the HLA types of our AIH patients,
which would contribute significantly to diagnosis
and subsequent treatment options.
In the current study, we found that HLA-DQ5
is the most frequent phenotype of HLA antigens
in our AIH patients. In addition, it is rather sur-
prising that very low frequencies of A1 (n = 2/22),
B8 (n = 1/22) and DR3 (n = 0/22) were observed
in our study compared to reports from Western
countries, where these HLA antigens have long
been recognized to be independent risk factors
for AIH patients.2 It is of note that among the
prevalent types of HLA antigens reported in the
West, only HLA-DR4 showed a higher rate (36%)
in our AIH patients. It is possible that the low in-
cidence of A1, B8 and DR3 in our AIH patients is
just due to the low prevalence of these antigens
in the general population (Tables 2 and 3). DQ5
was found to be the principal risk factor for the
disease in this study, which is somewhat different
from the Western literature. In the white popula-
tion, it is known that AIH patients with HLA-DR
risk factors have established DQ linkages regard-
less of the disease state,18 DQ2 is commonly pres-
ent with HLA-DR3 and DQ7 or DQ8 commonly
present with HLA-DR4.18 A study from the Mayo
Clinic had found that DQ2, DQ4, DQ5, DQ6
and DQ7 shared positivity for patients with
HLA-DR3 and DR4, but the associations were of
low frequency and only reflected established
linkages.19 Only the DR3-DQ2 haplotype was
significant as a major risk factor in this report.
These observations have indicated that in white
populations, DQ antigen shared positivity in 
patients with HLA-DR risk factors but is itself not
a promising site for a susceptibility gene. The dis-
crepancies of the HLA genotypes existing among
different countries and geographical regions are
not clear. These may be due to racial variations,
environmental and geographical factors, or disease
heterogeneity in the distribution of HLA antigens
or HLA alleles among populations.20
Reports from various countries have shown
that the genetic association of AIH with HLA-DR4
is quite a universal finding for many geographi-
cal regions.2–5,7 A strong association of HLA-DR4
with AIH was found in the Caucasians of northern
Europe and North America, in Argentineans, in
Japanese, and in Chinese patients from Shanghai.
In the present study, we also observed a higher
rate of HLA-DR4 (36%) in our AIH patients, but
this did not reach statistical significance when
compared to the normal population control.
Since the number of cases in the present study
was not large enough, a further larger population
study is needed to determine whether or not
HLA-DR4 exerts a strong genetic association with
our AIH patients, and hence we do not exclude
HLA-DR4 as a risk factor.
The rapid accumulation of scientific informa-
tion has revealed that the genetic background of
AIH may be very complex, and further investiga-
tion into the allelic subtypes of HLA antigens
will help to define more clearly the susceptible
population of AIH.13,21,22 In recent years, high
resolution DNA-based techniques have identi-
fied DRB1*0301 and DRB1*0401 as the main 
alleles to be associated with type 1 AIH.13 We are
also in the midst of another study to characterize
our AIH patients into HLA allelic subgroups.
To date, in this preliminary study, we conclude
that HLA-DQ5 is significantly more frequent
among AIH patients in Taiwan, and HLA-A2 DQ5
was the most common haplotype seen in this
study. The well known HLA A1, B8 and DR3
prevalent in Western countries were rare in our
AIH population, except for HLA-DR4. Further 
efforts to investigate the DQ and DR specific
amino acid sequence of our cases at the nucleotide
level are underway.
HLA-DQ5 association with autoimmune hepatitis
J Formos Med Assoc | 2007 • Vol 106 • No 12 1067
References
1. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of 
autoimmune hepatitis. Dig Dis Sci 2002;47:2139–50.
2. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility
to autoimmune chronic active hepatitis: human leukocyte
antigens DR4 and A1-B8-DR3 are independent risk factors.
Hepatology 1991;13:701–6.
3. Seki T, Ota M, Furuta S, et al. HLA class II molecules and
autoimmune hepatitis susceptibility in Japanese patients.
Gastroenterology 1992;103:1041–7.
4. Pando M, Larriba J, Fernandez GC, et al. Pediatric and
adult forms of type 1 autoimmune hepatitis in Argentina:
evidence for differential genetic predisposition. Hepatology
1999;30:1374–80.
5. Vazquez-Garcica MN, Alaez C, Olivo A, et al. MHC class II
sequences of susceptibility and protection in Mexicans
with autoimmune hepatitis. J Hepatol 1998;28:985–90.
6. Fainboim L, Canero VMC, Marcos CY, et al. Protracted,
but no acute, hepatitis A virus infection is strongly associated
with HLA-DRB*1301, a marker for pediatric autoimmune
hepatitis. Hepatology 2001;33:1512–7.
7. Qiu DK, Ma X. Hepatitis and hepatocellular carcinoma 
relationship between human leukocyte antigen-DRB1 
and autoimmune hepatitis type I in Chinese patients. 
J Gastroenterol Hepatol 2003;18:63–7.
8. Alvarez F, Berg PA, Bianchi FB, et al. International
Autoimmune Hepatitis Group report: review of criteria for
diagnosis of autoimmune hepatitis. J Hepatol 1999;31:
929–38.
9. Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of
HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology
1993;105:1502–7.
10. McFarlane IG. Pathogenesis of autoimmune hepatitis.
Biomed Pharmacother 1999;53:255–63.
11. Sandro V, Lorenza G, Franca M, et al. Epstein-Barr virus as
a trigger for autoimmune hepatitis in susceptible individuals.
Lancet 1995;346:608–9.
12. Gough A, Chapman S, Wagstaff K, et al. Minocycline 
induced autoimmune hepatitis and systemic lupus 
erythematous-like syndrome. Br Med J 1996;312:
169–72.
13. Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations
between alleles of the major histocompatibility complex
and type 1 autoimmune hepatitis. Hepatology 1997;25:
317–23.
14. Donaldson PT, Czaja AJ. Genetic effects on susceptibility,
clinical expression, and treatment outcome of type 1 
autoimmune hepatitis. Clin Liver Disc 2002;6:419–37.
15. Koay LB, Lin CN. The clinical study of autoimmune hepatitis.
J Intern Med Taiwan 2005;16:18–25.
16. Koay LB, Lin CY, Tzai SL, et al. Type 1 autoimmune hepatitis
in Taiwan: diagnosis using the revised criteria of Interna-
tional Autoimmune Hepatitis Group. Dig Dis Sci 2006;51:
1978–84.
17. Boberg KM. Prevalence and epidemiology of autoimmune
hepatitis. Clin Liver Dis 2002;6:347–59.
18. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for
factors of the HLA system, 1991. Hum Immunol 1992;
34:4–18.
19. Czaja AJ, Moore SB. HLA-DQ associations in type 1 autoim-
mune hepatitis. Mayo Clin Proc 1995;70:1154–60.
20. Czaja AJ. Current concepts in autoimmune hepatitis. 
Ann Hepatol 2005;4:6–24.
21. Yoshizawa K, Ota M, Katsuyama Y, et al. Genetic analysis
of the HLA region of Japanese patients with type 1 
autoimmune hepatitis. J Hepatol 2005;42:578–84.
22. Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of
HLA haplotypes in autoimmune hepatitis type 1: identify-
ing the major susceptibility locus. Human Immunol 2001;
62:165–9.
L.B. Koay, et al
1068 J Formos Med Assoc | 2007 • Vol 106 • No 12
